Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

REL-0609 trial's hypothesis is that repeated loading doses of clopidogrel (600 mg) administration in addition to high dose of clopidogrel continuous therapy (150 mg/day) results in higher inhibition of the platelets' aggregation in patients with myocardial infarction undergoing interventional treatment comparing to the standard therapy. Such treatment strategy will not cause increased risk of bleeding complications. In many trials treatment with to repeated loading doses of clopidogrel together with high dose of clopidogrel continuous therapy resulted in: MACE reduction, improvement of the long term therapy results, lower risk of ischemic complications. Currently, data regarding to the results of the above treatment are still limited.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity

NCT00638326

Stable Angina Pectoris Ad Hoc Percutaneous Coronary Intervention

TERMINATED PHASE3

Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS

NCT00444132

Clopidogrel Non-Responsiveness

COMPLETED PHASE3

Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction

NCT00714961

Acute Coronary Syndromes

COMPLETED PHASE3

Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function

NCT00693069

Coronary Artery Disease

COMPLETED PHASE3

Clopidogrel Efficacy and Acute Coronary Syndromes

NCT00839267

Acute Myocardial Infarction

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objectives of the study is:

* to evaluate the effect of the repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy (150 mg/day) on the platelet aggregation inhibition in patients with myocardial infarction undergoing interventional treatment
* to evaluate the safety of the repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy (150 mg/day) in patients with myocardial infarction undergoing interventional treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clopidogrel - Repeated Loading Dose

repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)

Group Type EXPERIMENTAL

Clopidogrel

Intervention Type DRUG

repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)

Clopidogrel - standard of care

no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)

Group Type ACTIVE_COMPARATOR

Clopidogrel

Intervention Type DRUG

no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clopidogrel

repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)

Intervention Type DRUG

Clopidogrel

no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

•≥18 years of age,

* Myocardial Infarction with or without ST segment elevation,
* clopidogrel treatment (confirmed administration of loading dose of 600 mg or chronic therapy of 75 mg/day),
* signed written informed consent.

Exclusion Criteria

* prior administration of fibrinolytic therapy and/or GP IIb/IIIa inhibitors within the last 14 days,
* prior administration of prasugrel within the last 14 days,
* subject with known hypersensitivity to the active ingredient or other components of the product
* increased risk of bleeding complications:bleeding diathesis, thrombocytopenia (platelet count \< 100 000/mm3), oral anticoagulant therapy (INR \>1.6), uncontrolled hypertension (systolic blood pressure \>200 mmHg), major bleeding, trauma or surgery within the last 30 days,
* acute renal failure,
* acute liver failure,
* pregnancy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No